Status | Study |
Recruiting |
Study Name: Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2012-05-16 Interventions: Drug: Cladribine and pegylated interpheron alpha-2a Cladri |
Completed |
Study Name: Imatinib in KIT-negative Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2011-02-16 Interventions: Drug: Imatinib Mesylate In |
Recruiting |
Study Name: Evaluation of Response of Dasatinib to Treat Mastocytosis Condition: Systemic Mastocytosis Date: 2009-09-16 Interventions: Drug: Dasatinib Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient w |
Terminated |
Study Name: Obatoclax for Systemic Mastocytosis Condition: Leukemia Systemic Mastocytosis Date: 2009-06-09 Interventions: Drug: Obatoclax Mesylate 30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle. |
Recruiting |
Study Name: A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap Condition: Smouldering Systemic Mastocytosis Indolent Date: 2008-12-22 Interventions: Drug: masitinib (AB1010) masit |
Active, not recruiting |
Study Name: Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Condition: Leukemia Date: 2008-10-28 Interventions: Drug: Midostaurin (PKC412) Midostaurin was provided as 25 mg soft gelatin capsules for oral administrati |
Completed |
Study Name: Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis Condition: Non Neoplastic Condition Precancerous Condition Date: 2008-10-08 Interventions: Drug: thalidomide |
Completed |
Study Name: Use of Tamoxifen in Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2007-12-25 |
Completed |
Study Name: Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Condition: Leukemia Systemic Mastocytosis Date: 2007-06-26 Interventions: Drug: Ontak (Denileukin Diftitox) 9 µg/kg by vein Days 1-5 of a 21 day cycle. |
Completed |
Study Name: Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2007-03-19 Interventions: Drug: RAD001 (Everolimus) Oral RAD001 10 mg daily for 30 days |